A socially oriented non-financial development institution and a major organizer of nationwide and international conventions; exhibitions; and business, public, youth, sporting, and cultural events.

The Roscongress Foundation is a socially oriented non-financial development institution and a major organizer of nationwide and international conventions; exhibitions; and business, public, youth, sporting, and cultural events. It was established in pursuance of a decision by the President of the Russian Federation.

The Foundation was established in 2007 with the aim of facilitating the development of Russia’s economic potential, promoting its national interests, and strengthening the country’s image. One of the roles of the Foundation is to comprehensively evaluate, analyse, and cover issues on the Russian and global economic agendas. It also offers administrative services, provides promotional support for business projects and attracting investment, helps foster social entrepreneurship and charitable initiatives.

Each year, the Foundation’s events draw participants from 208 countries and territories, with more than 15,000 media representatives working on-site at Roscongress’ various venues. The Foundation benefits from analytical and professional expertise provided by 5,000 people working in Russia and abroad.

The Foundation works alongside various UN departments and other international organizations, and is building multi-format cooperation with 173 economic partners, including industrialists’ and entrepreneurs’ unions, financial, trade, and business associations from 78 countries worldwide, and 179 Russian public organizations, federal and legislative agencies, and federal subjects.

The Roscongress Foundation has Telegram channels in Russian t.me/Roscongress, English – t.me/RoscongressDirect, and Spanish t.me/RoscongressEsp. Official website and Information and Analytical System of the Roscongress Foundation: roscongress.org.

RC personal account
Восстановление пароля
Введите адрес электронной почты или телефон, указанные при регистрации. Вам будет отправлена инструкция по восстановлению пароля.
Некорректный формат электронной почты или телефона
Vladimir Shipkov

Vladimir Shipkov

Executive Director, Association of International Pharmaceutical Manufacturers (AIPM)
Quotes
15.06.2022
SPIEF 2022
Export Potential: EAEU and the Global Market
I think it is about time to use the experience of global regulators for the fast-developing areas and decision-making mechanisms. It is regulatory reliance and trust. It does not mean acknowledging the results of other countries’ regulators. It means taking them into account. Taking them into account when making our own decisions. If some of the original innovative products are already registered in other markets, in other jurisdictions that can be respected within our national jurisdiction or within the Eurasian Economic Union, why don’t we factor it in when making important decisions on ensuring accessibility of – let’s say – innovative products in our national healthcare’s best interest
15.06.2022
SPIEF 2022
Export Potential: EAEU and the Global Market
I remember the times when very few people believed in the success of the Eurasian integration. However, I dare say that this project turned out to be a success thanks to the efforts of member countries’ regulators and business communities, the Eurasian Committee and the international industry. At least we can say so in terms of grounds for discussing a fairly ambitious task to develop the export potential of the EAEU pharmaceutical industry. <…> But first of all, we need to acknowledge and appreciate the first successful single market of the Eurasian Economic Union. This is the first pharmaceutical market. We cannot develop the expert potential without acknowledging this fact
15.06.2022
SPIEF 2022
Export Potential: EAEU and the Global Market
Initially, a different procedure for creating a single Eurasian market was conceived. However, administration and legal practices have led to its own peculiar bureaucracy and has become identical to primary registration in accordance with the requirements of the Eurasian Economic Union. This is not the way. It should not be this way. We will not be able to create an export or a pharmaceutical potential by 2025, if we do not dramatically simplify the conformity procedure. <…> Let’s make the confirmation and the GMP certificate issued in the Eurasian Union grounds for being included in the Eurasian register automatically or semi-automatically
15.06.2022
SPIEF 2022
Export Potential: EAEU and the Global Market
We applaud to the most recent decisions of the Eurasian Commission that will help create competitive Eurasian regulations. Regulations that would keep up with national-level decision making – first of all, in the Russian Federation. To be honest, we were a bit sceptical at first, because we feared that national regulators may not have been making decisions fast enough. The Government of the Russian Federation has been leading and driving these processes. However, thanks to our discussion with the Eurasian Commission and the regulators of all the countries, the Commission has joined the processes promptly and has now become the driver <…>. The key to joint success is smart and harmonized regulations
07.06.2019
SPIEF 2019
Innovative development of the pharmaceutical and biotech industry in Russia: keys to success
Just 15 companies that are global members of our Association made an unprecedented investment in innovation last year – USD 10 billion. <…> This is long-term high-risk investment that should be properly protected. <…> We need to create a culture of treating intellectual property with respect and awe
08.06.2019
SPIEF 2019
Priority Strategies in the Supply of Drugs
We must hear and listen to the professional community. I think we already have a positive dynamic in this regard
13.02.2019
Healthy Life Forum: Towards 80+ 2019
A System of Universal Medicine Provision: Key to Achieving the National Goal
In order to increase access to modern, innovative medicines, we need smart regulations and equally smart enforcement. Unfortunately, we’ve recently been creating regulations that create barriers. We’re not treating regulation as a science
26.05.2018
SPIEF 2018
Providing Medications to the Russian Population
We must all work together to propose solutions – market participants, producers, distributors, patients, and doctors